LNTH Lantheus Holdings, Inc.
Price Chart
Executive Summary
Lantheus announced that an image from its LNTH-2513 (18F-GP1) PET/CT trial for deep vein thrombosis (DVT) was awarded SNMMI's Image of the Year, with Phase 2 data showing 95% sensitivity and 92% specificity for proximal DVT. This is a non-financial pipeline milestone that validates the platform's potential in thromboembolic imaging but does not change near-term revenue or earnings.
Actionable Insight
This is a non-financial pipeline catalyst that supports the radiopharmaceutical thesis but does not alter near-term fundamentals. Monitor for FDA meeting minutes or pivotal trial initiation for LNTH-2513; no immediate trading catalyst.
Key Facts
- LNTH-2513 (18F-GP1) PET/CT awarded SNMMI 2026 Image of the Year for DVT detection.
- Investigator-initiated trial (n=46) showed 95% sensitivity and 92% specificity for proximal DVT vs venous ultrasonography.
- LNTH-2513 identified concomitant pulmonary embolism in 22 of 46 patients.
- No drug-related adverse events reported; well-tolerated.
- LNTH-2513 is an investigational agent; no regulatory submission or commercial timeline provided.
Financial Impact
No financial impact disclosed; LNTH-2513 is pre-commercial with no revenue contribution.
Risk Factors
- LNTH-2513 remains investigational; regulatory approval and commercial launch are uncertain.
- Competing imaging modalities (e.g., ultrasound, CT angiography) are well-established for DVT.
- No timeline for pivotal trial or FDA submission provided.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305065 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
3d ago
|
Press Release
| $96.30 $100.25 | ▲ +4.10% | ▲ +4.80% | $100.96 (+4.83%) |
|
May 7, 2026
29d ago
|
8-K
| $91.00 $93.06 | ▲ +2.26% | ▲ +1.43% | $100.96 (+10.94%) |
|
Mar 20, 2026
10w ago
|
DEFA14A
| $75.73 $74.24 | ▼ −1.97% | ▼ −1.61% | $100.96 (+33.31%) |
|
Mar 6, 2026
12w ago
|
Press Release
| $80.01 $83.22 | ▲ +4.01% | ▲ +4.20% | $100.96 (+26.18%) |
|
Feb 26, 2026
14w ago
|
8-K
| $75.43 $74.91 | ▼ −0.69% | ▼ −0.24% | $100.96 (+33.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access